PBPhilip Britton

Philip Britton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philip Britton has a total of 576 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced respiratory syncytial virus surveillance of young children admitted to the Sydney Children’s Hospitals Network, 2019–2023

    by Gemma L. Saravanos, Kathryn Meredith, Shirley Wong, Rebecca Burrell, Adam Bartlett, Nusrat Homaira, Philip N. Britton, Rama Kandasamy

    Objectives: In this study, we aimed to comprehensively describe the clinical characteristics, management and outcomes of children with respiratory syncytial virus (RSV) disease admitted to the Sydney Children’s Hospitals Network (SCHN), determine the full burden of severe disease and identify population-specific risk factors for intensive care unit (ICU) admission. Study type: Multi-centre, retrospective cohort study conducted over 5 years. Methods: The study was conducted at two tertiary paediatric hospitals in metropolitan New South Wales, Australia, before implementation of government-funded immunisation programs against RSV in children. Participants were children aged <2 years hospitalised with laboratory-confirmed RSV from 1 January 2019 to 31 December 2023, comprising all ICU admitted, and a random sample of non-ICU admitted patients. The main outcome measures were characteristics and incidence rate of RSV hospitalisations and ICU admissions among children aged <2 years. Results: Over a 5-year period, 4414 children were hospitalised with laboratory-confirmed RSV, of whom 11.3% (499/4414) were admitted to ICU. The median age was younger in the ICU cohort (n = 499) compared with the non-ICU sample (n = 1000; 3.3 vs 7.1 months, P < 0.0001). Factors associated with higher odds of ICU admission in multivariate logistic regression were decreasing month of age (OR 1.10, 95% CI 1.06–1.11), prematurity (OR 2.17, 95% CI 1.61–2.91), Indigenous identity (OR 4.10, 95% CI 2.30–7.56) and cardiac disease (OR 3.39, 95% CI 2.06–5.70). The average hospitalisation incidence rate was 1615 per 100,000 (95% CI 1565–1666), with higher rates among children aged <1 year, 2141 per 100,000 (95% CI 2061–2224) compared with those aged 1–2 years, 1088 per 100,000 (95% CI 1030–1148). Conclusions: RSV immunisation programs are expected to substantially reduce the burden of hospitalisation among Australian children in their first year of life. Children who are Indigenous, were born prematurely or have heart disease are at greatest risk of severe disease and may benefit from extended preventative programs.

  • Open Access

    Long-term outcomes of childhood encephalitis in Australia: burden and predictors from the Australian childhood encephalitis (ACE) prospective multicentre cohort

    by Gautam J. Rao, Russell C. Dale, Rebecca Burrell, Luis Furuya-Kanamori, Katherine Phan, Christopher C. Blyth, Jim P. Buttery, Julia E. Clark, Nigel W. Crawford, Helen S. Marshall, et al.

  • Open Access

    Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

    by Ushma Wadia, Peter C. Richmond, Philip N. Britton, Jeremy Carr, Julia E. Clark, Nigel W. Crawford, Te-Yu Hung, Helen S. Marshall, Kristine K. Macartney, Nicholas J. Wood, et al.


  • Open Access

    In‐Hospital Complications of Influenza A and B Among Hospitalized Australian Children in the Post‐COVID Era

    by Angelica Wei Wen Hii, Jahidur Rahman Khan, Kishor Kumar Paul, Mei Chan, Nan Hu, Brendan McMullan, Philip N. Britton, Adam W. Bartlett, Rama Kandasamy, Louisa Owens, et al.

    Background: Influenza is a leading cause of pediatric hospitalizations, with clinical presentations and outcomes varying between types A and B. This study compared the clinical characteristics and complications of children hospitalized with influenza A and B at the Sydney Children's Hospitals Network (SCHN) in the post‐COVID era. Methods: We conducted a retrospective cohort study of children < 18 years admitted to SCHN with influenza during 2022–2023. Data on patient demographics, clinical presentations, complications, and management were extracted from electronic medical records. Group comparisons used chi‐square or Fisher's exact tests, and modified Poisson regression estimated adjusted risk ratios (RRs) with 95% confidence intervals (CIs) for key clinical outcomes. Results: Among 704 influenza hospitalizations, 480 (68.2%) were due to influenza A and 224 (31.8%) to influenza B. Influenza B hospitalizations were more frequent in older children aged 5–< 18 years (67.4% vs. 57.7%) and associated with myalgia and pharyngitis, whereas influenza A hospitalizations were more common in children < 5 years (42.3% vs. 32.6%) and linked to cough, wheeze, and seizures. Although less common, influenza B hospitalizations exhibited greater clinical severity, with higher risks of noninvasive respiratory support (RR = 2.94; 95% CI 1.49–5.81) and intensive care unit (ICU) admission and/or mechanical ventilation (RR = 3.23; 95% CI 1.43–7.32). Conclusions: Influenza B, though less prevalent, was associated with greater severity, particularly in older children. These findings underscore the importance of continued protection against both influenza types and support consideration of expanding vaccine access to children aged 5 years and older.

  • Open Access

    Respiratory Syncytial Virus Transmission in Closed Community Settings That Include Children: A Systematic Review and Meta‐Analysis

    by Gemma L. Saravanos, Mari Takashima, Asmaa El‐Heneidy, Catherine King, Miroslava Ross, Anita Williams, Robert S. Ware, Philip N. Britton

    Background: Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections in children and is predominantly acquired and spread in community settings such as households and early childhood education centres. This review aims to synthesise the available evidence on RSV transmission in closed community settings that include children, with a focus on secondary attack rates (SAR). Methods: We conducted a systematic review informed by Cochrane guidelines. We searched Ovid Medline, Ovid Embase Classic and Embase, Ovid Global Health, Cochrane Library, Web of Science, and Scopus from inception to March 2025. Grey literature was searched through Google Scholar and relevant websites. We included articles reporting primary data on RSV SAR or other attack rates in closed community settings that included children aged under 18 years. Two reviewers independently screened articles, extracted data, and assessed study quality using a modified Newcastle–Ottawa Scale. Random‐effects meta‐analysis was performed for SAR and attack rates. Subgroup analyses explored outcomes by study design, study setting and participant age. Results: A total of 38 articles were eligible and reported data from 30 unique study populations from 1956 to 2023 spanning 12 countries. Study settings included households ( n = 19), early childhood education and care ( n = 6) and residential care ( n = 5). Pooled household SAR was 23.8% (95% CI: 16.5–30.0%) across all ages and 26.8% (95% CI: 15.5–38.2%) for children aged less than 5 years. Pooled outbreak attack rate among children in early childhood education and residential care was 59.2% (95% CI: 31.7–86.8%). There was substantial heterogeneity of methods, reporting and outcomes across studies. Conclusion: Risk of RSV transmission in closed community settings that include children is substantial, yet current evidence is limited. Well‐designed transmission studies, particularly in early childhood education and care settings, are needed to support disease prevention and control, and to optimise population‐level modelling.


  • Open Access

    The Evolving Epidemiology of Invasive Pneumococcal Disease in Australian Children: A Multicentre Retrospective Observational Study

    by Phoebe C M Williams, Annaleise Howard Jones, Robert Duguid, Linny K Phuong, Amanda Gwee, Niall Johnston, Coen Butters, Shahin Oftadeh, Sharon Chen, Archana Koirala, et al.

    Background: In Australia, high pneumococcal conjugate vaccine (PCV) coverage has been achieved, yet invasive pneumococcal disease (IPD) continues to cause a significant burden of disease. The epidemiology of IPD was altered by the nonpharmaceutical interventions (NPIs) used to control the coronavirus disease (COVID-19) pandemic. We aimed to analyze this impact on the clinical characteristics associated with IPD in Australian children. Method: We systematically evaluated the clinical and microbiological characteristics of IPD in children (14 days; 13% vs 1%, P = .001). Conclusions: Alternations in the prevalence of respiratory viral transmission influence the epidemiology and clinical presentation of IPD. Newer PCVs and the implementation of immunization programs that target viral pathogens associated with IPD may reduce the ongoing burden of IPD in children.

  • Open Access

    Lesson From Practice: Not Gone, Should Not Be Forgotten: Recognising PIMS ‐ TS Cases in a Post‐Pandemic World

    by Rana Sawires, Anneke Engwerda, Mehyar Khair Baik, Philip N. Britton, David P. Burgner

    We describe the clinical presentation, laboratory findings and complications of severe paediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS‐TS), also known as multisystem inflammatory syndrome in children in a 16‐year‐old female diagnosed in June 2025. This case highlights the importance of prompt diagnosis of PIMS‐TS in the post‐coronavirus disease 2019 pandemic era to ensure timely and appropriate management.

  • Open Access

    Empirical Antibiotic Activity and Outcomes in Pediatric Gram-negative Bloodstream Infections: A Rank-based Composite Outcome Analysis

    by Sophie C H Wen, Melissa J Hardy, Abdullah T Aslan, Patrick N A Harris, Mark D Chatfield, Colleen L Lau, Geoffrey Spurling, Julia E Clark, Sonia Dougherty, Christopher C Blyth, et al.

    Background: Timely active empirical therapy (AET) may improve outcomes following bloodstream infection. In high-income settings, low pediatric mortality following gram-negative bloodstream infection (GNBSI) limits its value as a sole endpoint. Composite measures that incorporate multiple clinically relevant outcomes may detect differences more readily. We assessed the effect of AET on clinical outcomes in pediatric GNBSI. Methods: We analyzed data from a prospective surveillance study of hospitalized Australian children with GNBSI. A ranked composite endpoint included 30-day all-cause mortality (30D ACM), time to death, intensive care unit (ICU) admission, relapse, and hospitalization duration. Baseline differences were adjusted using inverse probability of treatment weighting. Generalized pairwise comparison (GPC) generated win statistics. Analyses were stratified by comorbidity, acquisition setting, and organism. Results: Active empirical therapy occurred in 597 episodes and inactive empirical therapy (IET) in 62. Median treatment duration was similar (AET 10 vs IET 11 days, P = .44). Generalized pairwise comparison analysis showed an adjusted win ratio of 1.04 (95% CI .72–1.52, P = .83), indicating no significant difference. Contributions from each composite component (AET vs IET) were the following: 30D ACM (2.2% vs 1.3%), time to death (0.02% vs 0.01%), ICU admission (7.5% vs 9.1%), relapse (2.6% vs 1.4%), and hospitalization duration (37.3% vs 36.0%). Stratified estimates were similar for comorbidity and acquisition. Conclusions: In this large multicenter pediatric GNBSI cohort, AET was not associated with improved outcomes. In high-resource settings, the impact of initial antibiotic activity may be smaller than traditionally assumed, though timely effective therapy remains essential for severe illness and low-resource settings.

  • Invasive Group A Streptococcal Infections Admitted to the Children's Hospital at Westmead—July 2018 to June 2023

    by Damian Lees, Philip Britton, Christine Lau, Jacqueline Dalby‐Payne

    Aim: Invasive Group A Streptococcal (iGAS) disease, associated with severe clinical outcomes and high morbidity and mortality, resurged globally following suppression during the early COVID‐19 pandemic. This retrospective observational study examines the frequency and clinical characteristics of iGAS cases admitted to an Australian tertiary paediatric hospital over 5 years (1 July 2018–30 June 2023). Methods: Data was gathered from electronic medical records of patients diagnosed with iGAS at The Children's Hospital at Westmead (CHW) during the study period. Demographic and clinical characteristics were analysed using Student T , Mann–Whitney U and Chi‐squared tests. Results: During the study, 61 iGAS patients were admitted to CHW. Admissions peaked in late 2018 and 2019 (22/61), declined sharply throughout 2020 and 2021 (5/61), and rose steeply in 2022 and early 2023 (34/61). The most common iGAS isolates were from blood (40%) and pleural fluid (28%), correlating with the most common iGAS diagnoses: pneumonia (41%), empyema (39%) and sepsis (28%). Many patients presented with cough (48%) and coryza (39%), with 63% of tested individuals having viral coinfections. Pre‐pandemic cases showed higher peak neutrophil counts (median: 22.8 × 10 9 /L vs. 17.1 × 10 9 /L, p = 0.04) and ICU admission rates (64% vs. 29%, p = 0.011), while other severity indices remained similar. Conclusions: This study observed an initial decline in iGAS cases during pandemic restrictions, followed by a resurgence post‐pandemic with no concurrent increase in severity. Viral coinfections were frequent, which may complicate clinical assessment, emphasising the need for heightened vigilance. The acute severity of iGAS highlights the importance of early recognition and management.